Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRPT
CUSIPN/A
Phone617-274-4000
Debt
Debt-to-Equity Ratio0.55
Current Ratio13.37
Quick Ratio12.28
Price-To-Earnings
Trailing P/E Ratio-93.71
Forward P/E Ratio-77.62
P/E GrowthN/A
Sales & Book Value
Annual Sales$154.58 million
Price / Sales65.15
Cash FlowN/A
Price / CashN/A
Book Value$12.21 per share
Price / Book12.59
Profitability
EPS (Most Recent Fiscal Year)($1.64)
Net Income$-50,680,000.00
Net Margins-83.88%
Return on Equity-24.68%
Return on Assets-16.89%
Miscellaneous
Employees255
Outstanding Shares65,530,000
Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions
What is Sarepta Therapeutics' stock symbol?
Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."
How were Sarepta Therapeutics' earnings last quarter?
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.23. The biotechnology company earned $64.60 million during the quarter, compared to analyst estimates of $65.31 million. Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. The business's revenue was up 295.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.57) earnings per share. View Sarepta Therapeutics' Earnings History.
When is Sarepta Therapeutics' next earnings date?
What price target have analysts set for SRPT?
22 brokers have issued 12 month price targets for Sarepta Therapeutics' shares. Their forecasts range from $56.51 to $189.00. On average, they anticipate Sarepta Therapeutics' stock price to reach $117.3255 in the next year. View Analyst Ratings for Sarepta Therapeutics.
Are investors shorting Sarepta Therapeutics?
Sarepta Therapeutics saw a decline in short interest in May. As of May 31st, there was short interest totalling 9,670,678 shares, a decline of 12.7% from the May 15th total of 11,082,340 shares. Based on an average trading volume of 1,112,935 shares, the short-interest ratio is presently 8.7 days. Approximately 15.7% of the company's shares are short sold. View Sarepta Therapeutics' Current Options Chain.
Who are some of Sarepta Therapeutics' key competitors?
Some companies that are related to Sarepta Therapeutics include Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Nektar Therapeutics (NKTR), BeiGene (BGNE), Genmab A/S (GNMSF) and Valeant Pharmaceuticals Intl (VRX).
Who are Sarepta Therapeutics' key executives?
Sarepta Therapeutics' management team includes the folowing people:
- Mr. Sandesh Mahatme LL.M., Exec. VP, CFO & Chief Bus. Officer (Age 53)
- Mr. David Tyronne Howton Jr., Sr. VP, Gen. Counsel & Corp. Sec. (Age 46)
- Mr. Alexander Bo Cumbo, Sr. VP & Chief Commercial Officer (Age 47)
- Ms. Shamim Ruff, Sr. VP & Chief Regulatory Affairs Officer (Age 58)
- Dr. Edward M. Kaye, Advisor (Age 69)
Has Sarepta Therapeutics been receiving favorable news coverage?
News coverage about SRPT stock has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sarepta Therapeutics earned a daily sentiment score of 0.07 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.67 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Sarepta Therapeutics' major shareholders?
Sarepta Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.25%), Eagle Asset Management Inc. (1.49%), JPMorgan Chase & Co. (1.08%), OppenheimerFunds Inc. (0.76%), Element Capital Management LLC (0.62%) and Lord Abbett & CO. LLC (0.61%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Jayant Aphale, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.
Which institutional investors are selling Sarepta Therapeutics stock?
SRPT stock was sold by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, BlackRock Inc., Lord Abbett & CO. LLC, Sphera Funds Management LTD., Oak Ridge Investments LLC, C WorldWide Group Holding A S, PNC Financial Services Group Inc. and Nuveen Asset Management LLC. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Sandesh Mahatme and Shamim Ruff. View Insider Buying and Selling for Sarepta Therapeutics.
Which institutional investors are buying Sarepta Therapeutics stock?
SRPT stock was acquired by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, JPMorgan Chase & Co., Franklin Resources Inc., Dimensional Fund Advisors LP, Element Capital Management LLC, Eventide Asset Management LLC, Sector Gamma AS and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Sarepta Therapeutics.
How do I buy shares of Sarepta Therapeutics?
Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sarepta Therapeutics' stock price today?
One share of SRPT stock can currently be purchased for approximately $153.69.
How big of a company is Sarepta Therapeutics?
Sarepta Therapeutics has a market capitalization of $6.90 billion and generates $154.58 million in revenue each year. The biotechnology company earns $-50,680,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Sarepta Therapeutics employs 255 workers across the globe.
How can I contact Sarepta Therapeutics?
Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]
MarketBeat Community Rating for Sarepta Therapeutics (SRPT)
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe SRPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
